
Elevation Oncology, Inc.
Elevation Oncology, Inc. (ELEV) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · ELEV · as of Jun 9, 2026
Key Statistics
Explore Elevation Oncology, Inc. Data
elev stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 12 · Buy rate: 25.0%
The ELEV analyst consensus is Hold, based on ratings from 12 Wall Street analysts over the past 3 months. The average 12-month price target is $9.00, representing +2365.75% upside from the current price of $0.36.
Competitors & Peers
elev competitorsStock Performance
Full HistoryAbout Elevation Oncology, Inc.
Elevation Oncology, Inc. is a clinical-stage biopharmaceutical company operating in the United States, committed to developing targeted cancer therapies for patients with specific genetic profiles. It…
what is elevation oncology, inc. · elev stock overview · elevation oncology, inc. company profile · who is elevation oncology, inc. ceo · elev NASDAQ · elevation oncology, inc. headquarters · elevation oncology, inc. business segments
About Stock Overview & Key Data
Elevation Oncology, Inc. (ELEV) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jun 25, 2021. As of the latest trading session, ELEV stock price is $0.36, with a market capitalization of $21.6M. The stock has returned -54.38% over the past 12 months and -38.67% year-to-date.
According to 12 Wall Street analysts, the consensus rating for Elevation Oncology, Inc. stock is Hold, with an average 12-month price target of $9.00. In fiscal year 2024, Elevation Oncology, Inc. reported revenue of — and net income of -$44.5M. For detailed data — including Elevation Oncology, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Elevation Oncology, Inc. (ELEV) stock price is $0.36. The stock is traded on NASDAQ under the ticker symbol ELEV. The 52-week range is $0.22 – $3.09.